Navigation Links
Royalty Pharma Statement Regarding Elan Proposal
Date:3/6/2013

is trading on a 6.8x 2015E projected earnings per share multiple[9]. The Proposal Price represents 30.6x Elan's 2015E Broker Projected Earnings Per Share. Were the Valeant or Jazz multiples referenced above to be applied to Elan's 2015E Broker Projected Earnings Per Share, they would imply a share price of US$3.15 and US$2.44 respectively. Equally, if the Proposal Price were divided by the Valeant or Jazz multiples referenced above respectively, the resulting implied earnings per share would be US$1.26 or US$1.62 respectively, both materially higher than Elan's 2015E Broker Projected Earnings Per Share of US$0.36.

Were Elan to distribute its net cash and the share price declined proportionally, the implied 2015E earnings per share multiple at the Proposal Price would be 16.7x[10], still materially above the corresponding multiples of Jazz or Valeant.

Elan management's strategy and the risks associated with itRoyalty Pharma believes that there are a number of significant risks associated with Elan's new business plan, many of which were identified in the Proposal Announcement. In particular, Royalty Pharma believes that each new investment made by Elan will be scrutinized to ascertain near-term value creation potential, thereby increasing the volatility in Elan Stock.

Royalty Pharma believes that these risks were demonstrated by Elan's February 6, 2013 announcement of the Tysabri Transaction, as well as by the change of heart evident in Elan's recent statements, following the receipt of Royalty Pharma's Proposal.

The day of the announcement of the Tysabri Transaction

On February 6, 2013, the day of the announcement of the Tysabri Transaction, Royalty Pharma believes that Elan revealed its true colors during the Tysabri Conference Call[11].

Elan stated that it would use "a majority of" the Tysabri Consideration for acquisitions in statements which Royalty Pharma believes were unclear and unfocused. Elan's statements
'/>"/>

SOURCE RP Management, LLC
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31

Related biology technology :

1. PDL BioPharma Provides Third Quarter 2012 Royalty Revenue Guidance of $85 Million
2. Cowen Healthcare Royalty Partners Raises $1 Billion
3. Array Biopharma and Global Blood Therapeutics Announce Drug Discovery Collaboration Focused on Hematology
4. Radiopharmaceuticals Market - Global Industry Analysis, Size, Share, Trends And Forecast, 2012 - 2018: MarketResearchReports.Biz
5. Alexandria Real Estate Equities, Inc. Announces Long-Term Lease with Leading Global Commercial-Stage Oncology Company, Onyx Pharmaceuticals, Inc., for New Build-to-Suit Facility in South San Francisco, California
6. AVANIR Pharmaceuticals To participate in two conferences in March
7. Favorable Scenario for Japan Pharma Industry in Coming Years, New Report Says
8. Hyperion Wins NDA Approval for UCD Drug Developed With Support from PharmaDirections
9. Technical Analysis on VIVUS and Achillion Pharma: Highlights on These Biotech Companies
10. Auxilium Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2012 Financial Results and Guidance for 2013
11. Serialization in Pharmaceuticals, a Webinar Presented by Xtalks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/tdw3ss/2015_strategies ) has ... in the UK Flow Cytometry Market" report ... a comprehensive analysis of the UK flow cytometry ... the French flow cytometry practice, as well as ... with significant market impact during the next five ...
(Date:6/1/2015)... -- Hutchison China MediTech Limited ("Chi-Med") ... ("AstraZeneca"), Hutchison MediPharma Limited,s ("HMP") collaboration partner, presented ... trial of HMP,s c-Met inhibitor savolitinib (AZD6094) combined ... lung cancer ("NSCLC"). AZD9291 is AstraZeneca,s ... (EGFR). Preliminary data on the activity of AZD9291 ...
(Date:5/31/2015)... The most heavily attended and popular session at ... Meeting – “The Plenary Session Including the Science of ... immunotherapy experts and members of the Society for Immunotherapy ... of the Department of Immunology at the University of ... received the Science of Oncology Award. The Science of ...
(Date:5/30/2015)... 2015 The Cholangiocarcinoma Foundation (CCF), ... bile duct cancer, announced today the first grant ... , The Foundation has awarded 5 ... country to raise awareness about cholangiocarcinoma and inspire ... that opens new pathways for diagnosis and drug ...
Breaking Biology Technology:Strategies in the UK Flow Cytometry Market 2015 2Savolitinib (AZD6094) Preliminary Phase Ib Clinical Data in Lung Cancer Presented at the 2015 ASCO Annual Meeting 2Savolitinib (AZD6094) Preliminary Phase Ib Clinical Data in Lung Cancer Presented at the 2015 ASCO Annual Meeting 3SITC Reports on Immunotherapy Insights and Data Featured at ASCO Plenary Session 2The Cholangiocarcinoma Foundation Awards $260,000 in Research Grants 2The Cholangiocarcinoma Foundation Awards $260,000 in Research Grants 3
... system, described as a breakthrough advancement in breast imaging, ... Drug Administration. , ,The system offers more evidence that ... tools that enable higher quality images for the detection ... GE Healthcare said the Senographe Essential system ...
... we asked William Yasnoff, founder of the eHealthTrust initiative, why ... that today are fractured and limited. , , ... William Yasnoff Yasnoff is a speaker at ... deliver a presentation titled "A New Patient-Centric and Sustainable Approach ...
... Madison, Wis. The Wisconsin Technology Council ... legislature with statewide membership arms, has announced eight additions ... have three-year terms and will join a board that ... business technology community. Electees include four technology organization leaders: ...
Cached Biology Technology:FDA approves advanced digital mammography system 2Interview: Dr. William Yasnoff on health records, part 2 2Interview: Dr. William Yasnoff on health records, part 2 3Interview: Dr. William Yasnoff on health records, part 2 4Interview: Dr. William Yasnoff on health records, part 2 5Interview: Dr. William Yasnoff on health records, part 2 6
(Date:5/18/2015)... , May 18, 2015 Fingerprint Cards ... FPC1020, FPC1025, FPC1145, FPC1155 and FPC1035 from one if its ... until and including Q3 2015 and the sensors will be ... Communicated order values for 2015 hereby amount to 740 MSEK ... 2015 of 140 MSEK and a number of smaller orders ...
(Date:5/14/2015)... , May 14, 2015  Verificient Technologies, ... verification and online remote proctoring, announced a ... (SaaS) company and creator of the Canvas ... the two companies will benefit from the ... As a fully integrated multifactor ...
(Date:5/11/2015)... , May 11, 2015  Through a well-rounded UAS delegation ... had a strong showing at AUVSI,s Unmanned 2015 conference ... of Ohio,s UAS industry met with ... from all points along the UAS ecosystem. ... (DDC) Vice President for Aerospace Rich Knoll . "If ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2Ohio Flies High at Unmanned '15, Sets Stage for Ohio UAS Conference 2
... free. But we'd all agree it's not worthless. So, ... , In 1997, the University of Vermont's Robert Costanza ... per year in a now-famous paper in the journal ... services" has bloomed. This young discipline studies how nature--through ...
... developed the first-ever genomic test to predict which patients ... and which patients can avoid the toxic regimen of ... save thousands of lives each year by recommending chemotherapy ... the test's developers at Duke's Institute for Genome Sciences ...
... therapy extends average life expectancy and decreases recurrences of ... lung cancer, according to researchers at Rhode Island Hospital. ... seven years, the median survival rate at three years ... months when thermal ablation was followed by radiation for ...
Cached Biology News:What's nature worth? New computer models tell all 2First-ever genomic test predicts which lung cancer patients need chemotherapy to live 2First-ever genomic test predicts which lung cancer patients need chemotherapy to live 3First-ever genomic test predicts which lung cancer patients need chemotherapy to live 4Combined treatment extends life expectancy for lung cancer patients 2Combined treatment extends life expectancy for lung cancer patients 3